For the Inventor, By the Inventor

Enter assignee name

Brighton, MA, United States of America

Compass Therapeutics LLC

USPTO Granted Patents = 15

Trademarks = 4

Forward Citations = 44

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Ugur Eskiocak (13 out of 14 patents)

Robert V Tighe, Iii (10 out of 10 patents)

Cheuk Lun Leung (10 out of 12 patents)

4. Michael March Schmidt (9 out of 9 patents)

5. Piotr Bobrowicz (8 out of 34 patents)

6. Paul Widboom (8 out of 8 patents)

7. Jason M Lajoie (7 out of 7 patents)

8. Bing Gong (3 out of 3 patents)

9. Rachel Rennard (3 out of 3 patents)

10. Amanda Frank Oliphant (3 out of 3 patents)

11. Benjamin Jacob Wolf (3 out of 4 patents)

12. Pearl Bakhru (3 out of 3 patents)

13. Diana I Albu (3 out of 3 patents)

15 patents: Sort by Forward Citations

1. 12503511 - MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF (2025-12-23),

2. 12467062 - TRANSGENIC MOUSE EXPRESSING COMMON HUMAN LIGHT CHAIN (2025-11-11),

3. 12460004 - Antibodies that bind CD277 and uses thereof (2025-11-04),

4. 12286483 - Method of treating cancer using CD137 antibodies and PD-1 antagonists (2025-04-29),

5. 11970538 - Multispecific binding constructs against checkpoint molecules and uses thereof (2024-04-30),

6. 11851497 - CD137 antibodies and tumor antigen-targeting antibodies and uses thereof (2023-12-26),

7. 11752207 - Agonist antibodies that bind human CD137 and uses thereof (2023-09-12),

8. 11718679 - CD137 antibodies and PD-1 antagonists and uses thereof (2023-08-08),

9. 11046769 - Multispecific binding constructs against checkpoint molecules and uses thereof (2021-06-29),

10. 10716851 - Agonist antibodies that bind human CD137 and uses thereof (2020-07-21),

11. 10434175 - Agonist antibodies that bind human CD137 and uses thereof (2019-10-08),

12. 10350292 - Agonist antibodies that bind human CD137 and uses thereof (2019-07-16),

13. 10279040 - Agonist antibodies that bind human CD137 and uses thereof (2019-05-07),

14. 10279039 - Agonist antibodies that bind human CD137 and uses thereof (2019-05-07),

15. 10279038 - Agonist antibodies that bind human CD137 and uses thereof (2019-05-07),

Company Overview

Compass Therapeutics LLC is a biotechnology company based in Brighton, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. The company specializes in harnessing the power of the immune system to create novel antibody-based treatments. With a commitment to advancing scientific research, Compass Therapeutics aims to address unmet medical needs through its proprietary technology platforms, which facilitate the discovery and development of next-generation therapeutics.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

15 Patents

#2 in Brighton, MA

#1,276 in Massachusetts

#21,052 in US

#39,921 in the World

Brighton, MA, United States of America

Compass Therapeutics LLC

Forward Citations = 44

13 inventors:

Ugur Eskiocak (13 out of 14 patents)

Robert V Tighe, Iii (10 out of 10 patents)

Cheuk Lun Leung (10 out of 12 patents)

4. Michael March Schmidt (9 out of 9 patents)

5. Piotr Bobrowicz (8 out of 34 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Compass Therapeutics LLC. Retrieved from https://idiyas.com/company/compass-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…